Literature DB >> 27617140

The Genetics of Ultra-Rare Renal Disease.

Melissa Muff-Luett1, Carla M Nester2.   

Abstract

The complement-mediated renal diseases are a group of ultra-rare renal diseases that disproportionately affect children and young adults and frequently lead to irreversible renal failure. Genetic mutations in alternate pathway of complement genes are pathomechanistically involved in a significant number of these unique diseases. Here, we review our current understanding of the role of genetics in the primary complement-mediated renal diseases affecting children, with a focus on atypical hemolytic uremic syndrome and C3 glomerulopathy. Also, included is a brief discussion of the related diseases whose relationship to complement abnormality has been suspected but not yet confirmed. Advances in genetics have transformed both treatment and outcomes in these historically difficult to treat, highly morbid diseases.

Entities:  

Keywords:  C3 glomerulopathy; atypical hemolytic uremic syndrome; complement; thrombotic microangiopathy

Year:  2016        PMID: 27617140      PMCID: PMC4918710          DOI: 10.1055/s-0036-1572515

Source DB:  PubMed          Journal:  J Pediatr Genet        ISSN: 2146-460X


  99 in total

1.  A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome.

Authors:  Tara K Maga; Nicole C Meyer; Craig Belsha; Carla J Nishimura; Yuzhou Zhang; Richard J H Smith
Journal:  Nephrol Dial Transplant       Date:  2010-10-25       Impact factor: 5.992

2.  C3 glomerulopathy: clinicopathologic features and predictors of outcome.

Authors:  Nicholas R Medjeral-Thomas; Michelle M O'Shaughnessy; John A O'Regan; Carol Traynor; Michael Flanagan; Limy Wong; Chia Wei Teoh; Atif Awan; Mary Waldron; Tom Cairns; Patrick O'Kelly; Anthony M Dorman; Matthew C Pickering; Peter J Conlon; H Terence Cook
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

3.  Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations.

Authors:  Fadi Fakhouri; Lubka Roumenina; François Provot; Marion Sallée; Sophie Caillard; Lionel Couzi; Marie Essig; David Ribes; Marie-Agnès Dragon-Durey; Frank Bridoux; Eric Rondeau; Veronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 10.121

4.  Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II).

Authors:  C Licht; S Heinen; M Józsi; I Löschmann; R E Saunders; S J Perkins; R Waldherr; C Skerka; M Kirschfink; B Hoppe; P F Zipfel
Journal:  Kidney Int       Date:  2006-04-12       Impact factor: 10.612

5.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

6.  Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases.

Authors:  Theresa Kwon; Alexandre Belot; Bruno Ranchin; Véronique Baudouin; Véronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Pierre Cochat; Chantal Loirat
Journal:  Nephrol Dial Transplant       Date:  2009-04-17       Impact factor: 5.992

Review 7.  Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches.

Authors:  Magdalena Riedl; Fadi Fakhouri; Moglie Le Quintrec; Damien G Noone; Therese C Jungraithmayr; Veronique Fremeaux-Bacchi; Christoph Licht
Journal:  Semin Thromb Hemost       Date:  2014-06-09       Impact factor: 4.180

8.  Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome.

Authors:  Lubka T Roumenina; Mathieu Jablonski; Christophe Hue; Jacques Blouin; Jordan D Dimitrov; Marie-Agnes Dragon-Durey; Mathieu Cayla; Wolf H Fridman; Marie-Alice Macher; David Ribes; Luc Moulonguet; Lionel Rostaing; Simon C Satchell; Peter W Mathieson; Catherine Sautes-Fridman; Chantal Loirat; Catherine H Regnier; Lise Halbwachs-Mecarelli; Veronique Fremeaux-Bacchi
Journal:  Blood       Date:  2009-07-07       Impact factor: 22.113

9.  C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.

Authors:  Agustín Tortajada; Hugo Yébenes; Cynthia Abarrategui-Garrido; Jaouad Anter; Jesús M García-Fernández; Rubén Martínez-Barricarte; María Alba-Domínguez; Talat H Malik; Rafael Bedoya; Rocío Cabrera Pérez; Margarita López Trascasa; Matthew C Pickering; Claire L Harris; Pilar Sánchez-Corral; Oscar Llorca; Santiago Rodríguez de Córdoba
Journal:  J Clin Invest       Date:  2013-06       Impact factor: 14.808

10.  Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation.

Authors:  Stefan Heinen; Andrea Hartmann; Nadine Lauer; Ulrike Wiehl; Hans-Martin Dahse; Sylvia Schirmer; Katharina Gropp; Tina Enghardt; Reinhard Wallich; Steffi Hälbich; Michael Mihlan; Ursula Schlötzer-Schrehardt; Peter F Zipfel; Christine Skerka
Journal:  Blood       Date:  2009-06-15       Impact factor: 22.113

View more
  2 in total

Review 1.  The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases.

Authors:  Joshua M Thurman; Ashley Frazer-Abel; V Michael Holers
Journal:  Arthritis Rheumatol       Date:  2017-10-17       Impact factor: 10.995

2.  Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?

Authors:  R Rodriguez-Monguio; T Spargo; E Seoane-Vazquez
Journal:  Orphanet J Rare Dis       Date:  2017-01-05       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.